Table IV.
Affinities of mutant AVR9 peptides as determined by competition-binding analyses
| Peptide | Kd | n |
|---|---|---|
| nm | ||
| Nonglycosylated | ||
| AVR9 (WT) | 0.41 | 16 |
| AVR9 (SY) | 0.40 | 2 |
| S05A (NC)a | 1.37 | 1 |
| RO8K (SY) | 0.18 | 2 |
| F10A (SY) | 7.72 | 3 |
| F21A (SY) | 12.5 | 5 |
| CPIb | No comp. (>10,000) | 1 |
| CTX-GVIAb | No comp. (>10,000) | 1 |
| Glycosylated | ||
| AVR9 (NC) | 9.76 | 3 |
| R08K (NC) | 7.55 | 3 |
| F10S (NC)c | 57.7 | 2 |
| R18K (NC) | 3.74 | 2 |
| H22L (NC) | 70.8 | 2 |
| L24S (NC)d | 127 | 2 |
| L24S (NC)d | 98.1 | 2 |
| H28L (NC)e | 37.4 | 1 |
AVR9 (WT) indicates wild-type AVR9 isolated from C. fulvum-infected tomato, (SY) indicates synthetic AVR9 peptides, and (NC) designates peptides isolated from PVX::Avr9-infected tobacco. n is the number of experiments. No comp., No competition of 125I-AVR9.
For S05A (NC) only one experiment could be performed because of the limited quantity of this peptide available.
Carboxy peptidase inhibitor (CPI) and ω-conotoxin GVIA (CTX-GVIA) are two peptides with structural homology to AVR9 (Isaacs, 1995).
Mixture of glycosylated and nonglycosylated peptides.
Results of two independent isolations from tobacco.
For H28L (NC) only one experiment could be performed because of the limited quantity of this peptide available.